[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21

Advertisement
4. Marler JJ, Rubin JB, Trede NS, Connors S, Grier H, Upton J, Mulliken JB, Folkman J: Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics; 2002 Feb;109(2):E37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases.
  • We describe 2 cases of angioblastoma, a rare, destructive pediatric tumor, treated with interferon alfa 2b (IFNalpha2b).
  • The second is a male neonate with a congenital tumor of the right hand that invaded the hypothenar eminence, destroying the fourth and fifth metacarpals.
  • Biopsy in both patients was interpreted as giant cell angioblastoma.
  • Angioblastoma is rare; there is only 1 reported case that necessitated amputation of an upper extremity, also initially recommended for our patient.
  • Because there is little experience with chemotherapy, permission was granted to employ an antiangiogenic regimen of IFNalpha2b.
  • Therapy was stopped after 3 years.
  • Eighteen months later, the patient remains disease-free.
  • IFNalpha2b therapy was discontinued after 1 year of treatment, and the child remains disease-free 2 years and 8 months later.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Giant Cell Tumors / drug therapy. Hemangioblastoma / drug therapy. Interferon-alpha / therapeutic use
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Fibroblast Growth Factor 2 / analysis. Hand. Humans. Infant. Infant, Newborn. Male. Neovascularization, Pathologic / drug therapy. Neovascularization, Physiologic / drug effects. Neovascularization, Physiologic / physiology. Palatal Neoplasms / drug therapy. Palatal Neoplasms / surgery. Recombinant Proteins. Skin Neoplasms / drug therapy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11826247.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 103107-01-3 / Fibroblast Growth Factor 2; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


5. Wackernagel W, Lackner EM, Pilz S, Mayer C, Stepan V: von Hippel-Lindau disease: treatment of retinal haemangioblastomas by targeted therapy with systemic bevacizumab. Acta Ophthalmol; 2010 Nov;88(7):e271-2
MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] von Hippel-Lindau disease: treatment of retinal haemangioblastomas by targeted therapy with systemic bevacizumab.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Hemangioblastoma / drug therapy. Molecular Targeted Therapy. Retinal Neoplasms / drug therapy. von Hippel-Lindau Disease / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20977691.001).
  • [ISSN] 1755-3768
  • [Journal-full-title] Acta ophthalmologica
  • [ISO-abbreviation] Acta Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


6. Reyns N, Assaker R, Louis E, Lejeune JP: Leptomeningeal hemangioblastomatosis in a case of von Hippel-Lindau disease: case report. Neurosurgery; 2003 May;52(5):1212-5; discussion 1215-6
MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal hemangioblastomatosis in a case of von Hippel-Lindau disease: case report.
  • OBJECTIVE AND IMPORTANCE: We report a unique case of extended leptomeningeal hemangioblastomatosis in a patient presenting with clinical von Hippel-Lindau disease.
  • CLINICAL PRESENTATION: A 50-year-old male patient had a history of three surgical procedures for the removal of a cerebellar hemangioblastoma, initially considered to be a recurrence of a sporadic form at the same location.
  • Seven years after the last operation, he developed chronic hydrocephalus.
  • Despite a ventriculoperitoneal shunt procedure, he experienced progressive worsening of gait disturbances, associated with touch numbness of the lower limbs and Parinaud's syndrome.
  • Pathological examination revealed leptomeningeal spread of the hemangioblastoma.
  • CONCLUSION: To the best of our knowledge, the clinical course of our patient, consistent with a thick leptomeningeal spread of hemangioblastoma from the posterior fossa to the sacrum, is unique.
  • Nevertheless, the short life expectancy of our patient is usual in von Hippel-Lindau disease.
  • This case report illustrates the crucial challenge to develop a specific drug therapy related to angiogenesis in von Hippel-Lindau disease.
  • [MeSH-major] Hemangioblastoma / etiology. Hemangioblastoma / pathology. Meningeal Neoplasms / etiology. Meningeal Neoplasms / pathology. von Hippel-Lindau Disease / complications. von Hippel-Lindau Disease / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12699568.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Lehman NL: The ubiquitin proteasome system in neuropathology. Acta Neuropathol; 2009 Sep;118(3):329-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In neuropathology, alteration of the UPS, or mutations in UPS target proteins may result in signaling abnormalities leading to the initiation or progression of tumors such as astrocytomas, hemangioblastomas, craniopharyngiomas, pituitary adenomas, and medulloblastomas.
  • In neurodegenerative diseases caused by the expression of mutant proteins, the cellular accumulation of these proteins may overload the UPS, indirectly contributing to the disease process, e.g., sporadic Parkinsonism and prion diseases.
  • The potential for the UPS as a target of pharmacological therapy is also discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4106-11 [17360485.001]
  • [Cites] Nature. 2009 May 28;459(7246):569-73 [19404257.001]
  • [Cites] Mol Cell. 2007 Apr 27;26(2):175-88 [17466621.001]
  • [Cites] Cell. 1999 Mar 5;96(5):635-44 [10089879.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5416-25 [18765533.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1997-2001 [12466115.001]
  • [Cites] J Neurosci. 2004 Sep 29;24(39):8410-5 [15456813.001]
  • [Cites] Cell Cycle. 2006 Jul;5(14):1569-73 [16861914.001]
  • [Cites] FASEB J. 2009 Sep;23(9):2820-30 [19369384.001]
  • [Cites] Neuron. 2005 Sep 1;47(5):629-32 [16129392.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):673-82 [12209156.001]
  • [Cites] Science. 2004 Feb 13;303(5660):1026-30 [14716021.001]
  • [Cites] Curr Top Dev Biol. 2006;76:89-101 [17118264.001]
  • [Cites] J Biol Chem. 2008 Feb 8;283(6):3316-28 [18070888.001]
  • [Cites] Annu Rev Biochem. 1998;67:425-79 [9759494.001]
  • [Cites] J Biol Chem. 2000 Aug 18;275(33):25733-41 [10823831.001]
  • [Cites] Ann Neurol. 2007 May;61(5):427-34 [17469116.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3557-60 [17690257.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12876-82 [14709552.001]
  • [Cites] J Biol Chem. 1992 Dec 5;267(34):24315-21 [1447181.001]
  • [Cites] Neurochem Int. 2007 Jul-Sep;51(2-4):105-11 [17586089.001]
  • [Cites] Cell Div. 2008 Apr 22;3:8 [18430235.001]
  • [Cites] J Clin Invest. 2007 Dec;117(12):3940-51 [17992259.001]
  • [Cites] Neuron. 2003 Mar 6;37(5):735-49 [12628165.001]
  • [Cites] Curr Biol. 1999 Feb 25;9(4):207-10 [10074433.001]
  • [Cites] J Neurochem. 2008 Dec;107(6):1471-81 [19094054.001]
  • [Cites] Toxicol Pathol. 2008 Feb;36(2):345-52 [18362199.001]
  • [Cites] J Biol Chem. 2000 Mar 24;275(12):8929-35 [10722740.001]
  • [Cites] Cell Signal. 2008 Oct;20(10):1725-39 [18602463.001]
  • [Cites] Acta Neuropathol. 2000 Jul;100(1):43-9 [10912919.001]
  • [Cites] Oncogene. 2004 Mar 25;23(13):2408-19 [14743209.001]
  • [Cites] J Child Neurol. 2008 Aug;23(8):912-5 [18487518.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21323-6 [12719435.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Apr 1;166(1):74-81 [16616114.001]
  • [Cites] Nat Neurosci. 2009 Jun;12(6):777-83 [19430469.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5484-9 [11729185.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2009;49:73-96 [18834306.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 Oct;79(10):1186-9 [18796596.001]
  • [Cites] J Biol Chem. 2004 Oct 1;279(40):42290-301 [15280365.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2007 Jun;78(6):626-8 [17210620.001]
  • [Cites] Mol Cancer Res. 2006 Oct;4(10):695-707 [17050664.001]
  • [Cites] Hum Mol Genet. 2008 Dec 15;17(24):3942-52 [18784277.001]
  • [Cites] PLoS One. 2009;4(3):e4973 [19319192.001]
  • [Cites] Acta Neuropathol. 2005 Jun;109(6):589-97 [15891929.001]
  • [Cites] J Cell Sci. 2004 Jan 15;117(Pt 2):281-92 [14657277.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2629-34 [19196987.001]
  • [Cites] Neurobiol Dis. 2005 Dec;20(3):646-55 [15936949.001]
  • [Cites] Trends Cell Biol. 2000 Dec;10(12):524-30 [11121744.001]
  • [Cites] J Cell Biol. 2008 Mar 24;180(6):1177-89 [18362179.001]
  • [Cites] Oncogene. 2008 Oct 9;27(46):6002-11 [18574468.001]
  • [Cites] J Neurochem. 2005 Mar;92(6):1531-41 [15748170.001]
  • [Cites] J Mol Biol. 2006 Mar 3;356(4):1027-35 [16405905.001]
  • [Cites] Cell Mol Life Sci. 2007 Mar;64(5):601-9 [17256086.001]
  • [Cites] Acta Neuropathol. 2008 Aug;116(2):159-67 [18553091.001]
  • [Cites] Cancer Res. 2009 Mar 15;69(6):2314-23 [19276349.001]
  • [Cites] Neurology. 2006 Sep 26;67(6):1074-7 [16807408.001]
  • [Cites] J Biol Chem. 2009 Feb 20;284(8):5030-41 [19098288.001]
  • [Cites] Neurosci Lett. 2008 Jan 31;431(2):141-5 [18191026.001]
  • [Cites] Cell. 2001 Jun 1;105(5):645-55 [11389834.001]
  • [Cites] Hum Mutat. 2000 Jul;16(1):89-90 [10874314.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 May;16(3):274-8 [18301241.001]
  • [Cites] Mol Biol Cell. 2003 Jul;14(7):2809-17 [12857866.001]
  • [Cites] EMBO J. 2009 Feb 18;28(4):372-82 [19153604.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Feb;66(2):152-7 [17279000.001]
  • [Cites] Arch Neurol. 2008 Aug;65(8):1031-8 [18695053.001]
  • [Cites] FASEB J. 2008 Nov;22(11):3785-94 [18632848.001]
  • [Cites] Hum Mol Genet. 2008 Mar 15;17(6):906-17 [18065497.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1793-805 [17456782.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5500-5 [15064394.001]
  • [Cites] J Neurosci. 2008 Dec 3;28(49):13285-95 [19052220.001]
  • [Cites] Genes Dev. 2006 Sep 1;20(17):2410-20 [16921029.001]
  • [Cites] PLoS Genet. 2009 Feb;5(2):e1000382 [19214209.001]
  • [Cites] Hum Mol Genet. 2001 May 15;10(11):1201-13 [11371513.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10094-104 [19074875.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2439-44 [10051661.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38851-61 [16157591.001]
  • [Cites] Mol Cell Biol. 2007 Nov;27(22):7955-65 [17875940.001]
  • [Cites] J Alzheimers Dis. 2009;17(2):319-25 [19363271.001]
  • [Cites] J Biol Chem. 2009 Apr 10;284(15):9796-803 [19218238.001]
  • [Cites] Oncogene. 2006 Jan 5;25(1):1-7 [16278683.001]
  • [Cites] Hum Mol Genet. 2009 Apr 15;18(8):1384-94 [19168853.001]
  • [Cites] Hum Mol Genet. 2008 Oct 15;17(20):3223-35 [18658163.001]
  • [Cites] Trends Cell Biol. 2002 May;12(5):216-21 [12062168.001]
  • [Cites] Nature. 2005 Nov 10;438(7065):224-8 [16227972.001]
  • [Cites] Neurobiol Dis. 2009 Jul;35(1):32-41 [19348945.001]
  • [Cites] Nat Struct Mol Biol. 2008 Dec;15(12):1334-42 [19043414.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(2):142-8 [10663629.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Jun 5;383(3):331-5 [19358826.001]
  • [Cites] Cell Signal. 2007 Mar;19(3):573-81 [17005371.001]
  • [Cites] Biochem J. 2009 Mar 15;418(3):643-50 [19049493.001]
  • [Cites] J Exp Med. 1996 Apr 1;183(4):1545-52 [8666912.001]
  • [Cites] Eur J Neurol. 2008 Aug;15(8):772-80 [18684309.001]
  • [Cites] Methods Enzymol. 2005;399:334-55 [16338367.001]
  • [Cites] Mol Cell. 2009 May 15;34(3):259-69 [19450525.001]
  • [Cites] Acta Neuropathol. 2008 Aug;116(2):147-57 [18536926.001]
  • [Cites] Drug News Perspect. 2007 Jul-Aug;20(6):365-70 [17925890.001]
  • [Cites] PLoS Genet. 2009 Feb;5(2):e1000383 [19214206.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3103-11 [15126347.001]
  • [Cites] J Neurochem. 2008 Jul;106(1):107-20 [18346206.001]
  • [Cites] Autophagy. 2008 Apr;4(3):372-4 [18216494.001]
  • [Cites] Biochemistry. 2007 Dec 25;46(51):14889-98 [18044963.001]
  • [Cites] J Pathol. 2003 Feb;199(2):259-66 [12533840.001]
  • [Cites] J Biol Chem. 1996 May 10;271(19):11339-46 [8626687.001]
  • [Cites] Neuron. 2003 Jul 17;39(2):217-25 [12873380.001]
  • [Cites] J Neurochem. 2004 Jul;90(2):379-91 [15228595.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Oct;66(10):884-91 [17917582.001]
  • [Cites] Mod Pathol. 2000 Apr;13(4):420-6 [10786809.001]
  • [Cites] Science. 2002 Jul 19;297(5580):365-9 [12130776.001]
  • [Cites] Nat Cell Biol. 2002 May;4(5):358-66 [11988738.001]
  • [Cites] Hum Mol Genet. 2005 Apr 15;14(8):1049-58 [15757975.001]
  • [Cites] J Biol Chem. 2009 Jan 30;284(5):3250-63 [19033443.001]
  • [Cites] Mol Cell Biol. 2005 Apr;25(7):2795-807 [15767683.001]
  • [Cites] FEBS J. 2009 Mar;276(5):1208-20 [19175675.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15690-5 [18836078.001]
  • [Cites] ScientificWorldJournal. 2008;8:421-33 [18454252.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):639-46 [18936941.001]
  • [Cites] J Biol Chem. 1982 Mar 10;257(5):2543-8 [6277905.001]
  • [Cites] J Biol Chem. 2002 Aug 9;277(32):28530-6 [12032152.001]
  • [Cites] Nature. 2004 Oct 14;431(7010):805-10 [15483602.001]
  • [Cites] Exp Neurol. 2007 Feb;203(2):531-41 [17097639.001]
  • [Cites] EMBO J. 1998 Jan 2;17(1):61-70 [9427741.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):184-92 [16453012.001]
  • [Cites] Dev Cell. 2003 Jun;4(6):799-812 [12791266.001]
  • [Cites] J Biol Chem. 2005 Sep 9;280(36):32026-34 [16040601.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2897-902 [19196961.001]
  • [Cites] Eur J Neurosci. 2008 Nov;28(10):1980-8 [19046380.001]
  • [Cites] Mol Cell Proteomics. 2008 Nov;7(11):2107-22 [18565875.001]
  • [Cites] Mol Biol Cell. 2006 Nov;17(11):4606-18 [16914519.001]
  • [Cites] Cell. 2009 May 15;137(4):609-22 [19450511.001]
  • [Cites] J Immunol. 1995 Oct 15;155(8):3750-8 [7561079.001]
  • [Cites] Nature. 2007 Aug 9;448(7154):704-8 [17687326.001]
  • [Cites] Science. 2001 Oct 5;294(5540):173-7 [11533444.001]
  • [Cites] Mol Cell Neurosci. 2002 Jun;20(2):298-306 [12093161.001]
  • [Cites] Mol Cell Biol. 2008 Sep;28(17):5275-87 [18573876.001]
  • [Cites] J Cell Biol. 2003 Oct 13;163(1):27-33 [14557245.001]
  • [Cites] Neuron. 2004 Nov 18;44(4):601-7 [15541309.001]
  • [Cites] J Neurosci. 2008 Jul 2;28(27):6926-37 [18596167.001]
  • [Cites] Genes Dev. 2006 Sep 15;20(18):2539-51 [16980583.001]
  • [Cites] J Clin Invest. 2009 Mar;119(3):650-60 [19229105.001]
  • [Cites] Mol Biol Cell. 2007 Apr;18(4):1129-42 [17229889.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):16041-6 [14668431.001]
  • [Cites] J Biol Chem. 2009 Mar 20;284(12):8083-92 [19112176.001]
  • [Cites] Mol Cancer Ther. 2009 Apr;8(4):930-9 [19372566.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):625-37 [18843496.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5906-11 [12384556.001]
  • [Cites] Nat Rev Neurosci. 2008 Nov;9(11):826-38 [18931696.001]
  • [Cites] Annu Rev Immunol. 2004;22:81-127 [15032575.001]
  • [Cites] J Biol Chem. 2008 Mar 21;283(12):7648-56 [18201976.001]
  • (PMID = 19597829.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K08 NS045077
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ubiquitin; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Number-of-references] 149
  • [Other-IDs] NLM/ PMC2716447
  •  go-up   go-down


8. Piribauer M, Czech T, Dieckmann K, Birner P, Hainfellner JA, Prayer D, Fazeny-Dörner B, Weinländer G, Marosi C: Stabilization of a progressive hemangioblastoma under treatment with thalidomide. J Neurooncol; 2004 Feb;66(3):295-9
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stabilization of a progressive hemangioblastoma under treatment with thalidomide.
  • After the second recurrence of spinal seeding in hemangioblastoma not associated to von-Hippel-Lindau disease, we treated an adult female patient with thalidomide 200 mg orally/day at night for longer than 1 year.
  • Magnetic resonance imaging (MRI) controls 1,6 and 11 months after begin of thalidomide treatment did not show further tumor progression.
  • There was no thalidomide associated side-effect in this patient until her death from pneumonia due to legionnaire's disease.
  • Antiangiogenic treatment with interferon (IFN) alpha-2a and IFN alpha-2b and with SU 5416 has been reported to be effective and well tolerated in several patients with previously progressive angioblastomas and hemangioblastomas.
  • This case adds further evidence of the efficacy of an antiangiogenic treatment concept in a progressive hemangioblastoma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Cerebellar Neoplasms / drug therapy. Hemangioblastoma / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Disease Progression. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33679-87 [10930413.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5356-62 [10498889.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(11):1147-56 [10592114.001]
  • [Cites] Bull World Health Organ. 1971;45(6):719-32 [4947831.001]
  • [Cites] Pediatrics. 2002 Feb;109 (2):E37 [11826247.001]
  • [Cites] Virchows Arch. 1999 Jul;435(1):8-12 [10431840.001]
  • [Cites] Circ Res. 1999 Aug 6;85(3):221-8 [10436164.001]
  • [Cites] Drugs. 2000 Aug;60(2):273-92 [10983733.001]
  • [Cites] J Neurosurg. 1989 Jan;70(1):24-30 [2909683.001]
  • [Cites] Nature. 1997 Apr 17;386(6626):671-4 [9109485.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5 [7513432.001]
  • [Cites] Neurosurg Rev. 2000 Mar;23(1):1-22; discussion 23-4 [10809480.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):25-9 [9665461.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4610-6 [10969814.001]
  • [Cites] Fertil Steril. 2001 Jan;75(1):131-5 [11163827.001]
  • [Cites] Cancer Treat Rev. 2000 Oct;26(5):351-62 [11006136.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1998 Jun;236(6):461-6 [9646092.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Dec;67(6):758-62 [10567493.001]
  • [Cites] Ophthalmology. 2002 Sep;109(9):1745-51 [12208726.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):510-6 [11297241.001]
  • [Cites] Nature. 1996 Apr 4;380(6573):435-9 [8602241.001]
  • [Cites] Neurosurg Rev. 1996;19(3):147-51 [8875501.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3906-27 [12228212.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] Expert Opin Biol Ther. 2002 Dec;2(8):953-66 [12517273.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22382-7 [11297551.001]
  • (PMID = 15015660.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


9. Drabko K, Choma M, Zaucha-Prazmo A, Wójcik B, Gorczyńska E, Kałwak K, Turkiewicz D, Słociak M, Ussowicz M, Dyla A, Chybicka A, Styczyński J, Debski R, Wysocki M, Goździk J, Ratajczak M, Kowalczyk JR: [Megachemotherapy and autologous hematopoietic stem cell transplantation in children with solid tumours excluding neuroblastoma--experience of Polish paediatric centres]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):785-92
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 25 children were treated for Ewing Sarcoma, 13 for rhabdomyosarcoma embryonale (RMS), 7 for germinal tumours, 6 for medulloblastoma, 4 for PNET, 4 for Wilm's tumours, 2 for glioblastoma and single patients with mesenchymoma, astrocytoma, ependymoma, angioblastoma, carcinoma ovarian and carcinoma embryonale glutei.
  • In 29 children MCH was introduced in first complete remission, in 14 the procedure was performed in second or subsequent remission and 24 patients did not achieve remission before megachemotherapy was started.
  • RESULTS: 30 children are alive (44%), 28 of them in complete remission of disease.
  • 23 out of 29 (79%) patients were transplanted in first complete remission and median observation time in that group is 29 months (range 2-74 months).
  • 39 patients relapsed at a median time 11 months after MCT and 37 of them subsequently died of disease at a median time of 16 months.
  • One toxic death was noted--it was a boy, transplanted with progressive disease.
  • It is a safe procedure especially when performed in remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Neoplasms / drug therapy. Neoplasms / surgery
  • [MeSH-minor] Academic Medical Centers. Adolescent. Antineoplastic Agents, Alkylating / administration & dosage. Bone Neoplasms / drug therapy. Bone Neoplasms / surgery. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Dose-Response Relationship, Drug. Ependymoma / drug therapy. Ependymoma / surgery. Female. Glioblastoma / drug therapy. Glioblastoma / surgery. Glioma / drug therapy. Glioma / surgery. Humans. Infant. Male. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / surgery. Meningioma / drug therapy. Meningioma / surgery. Neoplasm Staging. Oncology Service, Hospital. Poland. Remission Induction. Retrospective Studies. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / surgery. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317909.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating
  •  go-up   go-down


10. Sardi I, Sanzo M, Giordano F, Buccoliero AM, Mussa F, Aricò M, Genitori L: Monotherapy with thalidomide for treatment of spinal cord hemangioblastomas in a patient with von Hippel-Lindau disease. Pediatr Blood Cancer; 2009 Sep;53(3):464-7
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monotherapy with thalidomide for treatment of spinal cord hemangioblastomas in a patient with von Hippel-Lindau disease.
  • Von Hippel-Lindau (VHL) disease is a cancer-prone syndrome characterized by abnormalities in vascular proliferation and the development of both the visceral and CNS tumors.
  • Complications from hemangioblastoma are among the principal causes of death from this syndrome.
  • Antiangiogenic therapy has been used with different modalities in patients suffering from such complications.
  • Here, we describe an adolescent with VHL complicated by progressive, multifocal spinal hemangioblastomas.
  • Treatment with single-agent thalidomide over the course of 3 years was associated with an unexpected stabilization of the disease.
  • The antiangiogenic effect of thalidomide may be associated with the control of progressive hemangioblastoma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Hemangioblastoma / drug therapy. Spinal Cord Neoplasms / drug therapy. Thalidomide / therapeutic use. von Hippel-Lindau Disease / complications

  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19415739.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Vascular Endothelial Growth Factor A; 4Z8R6ORS6L / Thalidomide; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


11. Michels S, Messmer E, Sutter F, Kurz-Levin MM: [Intravitreal anti-VEGF therapy for capillary hemangioblastomas in von Hippel-Lindau disease]. Klin Monbl Augenheilkd; 2008 Apr;225(4):292-4
MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intravitreal anti-VEGF therapy for capillary hemangioblastomas in von Hippel-Lindau disease].
  • [Transliterated title] Intravitreale anti-VEGF-Therapie von retinalen kapillären Hämangioblastomen bei von-Hippel-Lindau-Erkrankung.
  • BACKGROUND: Up-regulated expression of the vascular endothelial growth factor (VEGF) in von Hippel-Lindau (VHL) disease has been postulated to induce retinal hemangioblastoma.
  • Intravitreal injections of anti-VEGF drugs might provide a new therapeutic option in this condition.
  • METHODS: In a single case decision a patient with active retinal hemangioblastomas due to VHL disease received repeated intravitreal injections of 0.5 mg ranibizumab.
  • RESULTS: Subsequent to intravitreal anti-VEGF therapy, the signs of activity of the retinal hemangioblastomas slowly regressed.
  • CONCLUSIONS: Intravitreal anti-VEGF therapy might, as monotherapy or as combination therapy, offer a new treatment option for retinal hemangioblastoma.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Hemangioblastoma / drug therapy. Retinal Neoplasms / drug therapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors. von Hippel-Lindau Disease / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Drug Administration Schedule. Endothelium, Vascular / drug effects. Female. Humans. Injections. Ophthalmoscopes. Ranibizumab. Visual Acuity / drug effects. Vitreous Body

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18401796.001).
  • [ISSN] 0023-2165
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; ZL1R02VT79 / Ranibizumab
  •  go-up   go-down


12. Tarantino R, Isidori A, Raco A, Missori P: Supratentorial hemangioblastoma in a patient with breast cancer. A case report. J Neurosurg Sci; 2000 Sep;44(3):137-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supratentorial hemangioblastoma in a patient with breast cancer. A case report.
  • Radio- and chemotherapy are advocated as an alternative to surgery in such patients.
  • A woman operated on for breast cancer 2 years earlier developed a cerebral lesion.
  • The lesion proved to be a supratentorial hemangioblastoma.
  • Neurosurgical treatment is recommended for patients with breast cancer who present a cerebral lesion, since a correct diagnosis may only be possible in the operating theater.
  • [MeSH-major] Breast Neoplasms / surgery. Cerebellar Neoplasms / surgery. Hemangioblastoma / surgery. Neoplasms, Second Primary / surgery

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11126448.001).
  • [ISSN] 0390-5616
  • [Journal-full-title] Journal of neurosurgical sciences
  • [ISO-abbreviation] J Neurosurg Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


13. Leonov MA, Makhmudov UB, Shimanskiĭ VN: [Hemangioblastomas of central nervous system]. Zh Vopr Neirokhir Im N N Burdenko; 2003 Oct-Dec;(4):39-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hemangioblastomas of central nervous system].
  • Hemangioblastomas of the central nervous system are benign, richly blood-supplied tumors that may be encountered in its any part, more commonly in the cerebellar hemispheres.
  • The histogenesis of hemangioblastomas has not been clearly ascertained so far.
  • Magnetic resonance imaging is the only valid diagnostic study of hemangioblastomas.
  • Hemangioblastomas may be presented as sporadic forms and a manifestation of the Hippel-Lindau syndrome.
  • In the latter case, hemangioblastomas are associated with angiomas of the retina and other viscera.
  • Surgery of hemangioblastomas is the basic treatment.
  • Radiosurgery is the method of choice for patients with Hippel-Lindau disease.
  • Chemotherapy is not indicated in hemangioblastomas.
  • Radiation therapy may be used after partial tumor removal.
  • [MeSH-major] Central Nervous System Neoplasms. Hemangioblastoma
  • [MeSH-minor] Humans. Intracranial Hypertension / etiology. Neurosurgical Procedures. von Hippel-Lindau Disease / diagnosis. von Hippel-Lindau Disease / genetics. von Hippel-Lindau Disease / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14959655.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia
  • [Number-of-references] 67
  •  go-up   go-down


14. Akay KM, Izci Y, Baysefer A, Atabey C, Kismet E, Timurkaynak E: Surgical outcomes of cerebellar tumors in children. Pediatr Neurosurg; 2004 Sep-Oct;40(5):220-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cerebellar tumors in childhood are generally associated with a favorable outcome if they are managed appropriately.
  • Histopathological diagnoses were as follows: pilocytic astrocytoma (48.2%); medulloblastoma (22.2%); ependymoma (18.5%); fibrillary astrocytoma grade III (3.7%); cystic oligodendroglioma (3.7%), and hemangioblastoma (3.7%).
  • Radiotherapy and chemotherapy are the adjuvant therapies according to the pathological diagnosis and the patient's age.
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Humans. Male. Neoplasm Invasiveness. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 S. Karger AG, Basel.
  • (PMID = 15687736.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


15. Kothbauer KF: Neurosurgical management of intramedullary spinal cord tumors in children. Pediatr Neurosurg; 2007;43(3):222-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgery is the best treatment and is also indicated to confirm the histological diagnosis.
  • In case of a low-grade tumor or a vascular lesion such as hemangioblastoma or cavernoma, a total or near-total resection is attempted.
  • For astrocytomas the resection almost always remains biologically incomplete, but a near-total resection is still associated with a long progression-free survival.
  • High-grade tumors are resected conservatively and treated with radiation and chemotherapy.
  • [MeSH-minor] Astrocytoma / diagnosis. Astrocytoma / mortality. Astrocytoma / surgery. Child. Disease-Free Survival. Ependymoma / diagnosis. Ependymoma / mortality. Ependymoma / surgery. Follow-Up Studies. Ganglioglioma / diagnosis. Ganglioglioma / mortality. Ganglioglioma / surgery. Hemangioblastoma / diagnosis. Hemangioblastoma / mortality. Hemangioblastoma / surgery. Humans. Magnetic Resonance Imaging. Monitoring, Intraoperative. Postoperative Complications / diagnosis. Postoperative Complications / etiology. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409792.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 98
  •  go-up   go-down


16. Aiello LP, George DJ, Cahill MT, Wong JS, Cavallerano J, Hannah AL, Kaelin WG Jr: Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology; 2002 Sep;109(9):1745-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416.
  • PURPOSE: To present a case of rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome and optic nerve head hemangioblastoma after systemic treatment with the vascular endothelial growth factor (VEGF) receptor inhibitor SU5416.
  • Central nervous system lesions were monitored by computed tomography (CT) and magnetic resonance imaging (MRI) scans.
  • Treatment involved the systemic administration of the VEGF receptor inhibitor SU5416.
  • MAIN OUTCOME MEASURES: Clinical presentation, visual acuity using Early Treatment Diabetic Retinopathy Study protocol, Humphrey automated perimetry, (Zeiss Humphrey Systems, Dublin, CA) Vistech contrast sensitivity (Vistech Consultants Inc., Dayton, OH) Farnsworth (Farnsworth-Munsell Color Services, New Windsor, NY) dichotomous panel D-15, retinal photography, fluorescein angiography, and CT and MRI scans.
  • RESULTS: Within 4 weeks of therapy, visual acuity had improved from 20/32(-2) to 20/16(-1), the visual field had expanded from being circumferentially constricted to within 8 degrees of fixation to normal, and contrast sensitivity improved in all but the lowest spatial frequency (1.5 cycles/degree).
  • Improvement has been maintained over 18 months with intermittent SU5416 therapy.
  • CONCLUSIONS: We report rapid, extensive, and durable recovery of visual function after systemic administration of the VEGF receptor inhibitor SU5416 to a patient with VHL syndrome and optic nerve head hemangioblastoma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Hemangioblastoma / drug therapy. Indoles / therapeutic use. Optic Disk / drug effects. Optic Nerve Neoplasms / drug therapy. Pyrroles / therapeutic use. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Receptors, Growth Factor / antagonists & inhibitors. Visual Acuity / physiology. von Hippel-Lindau Disease / drug therapy

  • Genetic Alliance. consumer health - Von Hippel-Lindau syndrome.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12208726.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Indoles; 0 / Pyrroles; 0 / Receptors, Growth Factor; 71IA9S35AJ / Semaxinib; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


17. Girmens JF, Erginay A, Massin P, Scigalla P, Gaudric A, Richard S: Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. Am J Ophthalmol; 2003 Jul;136(1):194-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas.
  • PURPOSE: To test the efficacy of the novel vascular endothelial growth factor (VEGF) receptor inhibitor SU5416, in a case of refractory von Hippel-Lindau (VHL) retinal hemangioblastoma (RHB).
  • A 30-year-old woman presenting with VHL disease and multiple RHB on her only eye, refractory to conventional treatments, had decreased visual acuity due to cystoid macular edema (CME).
  • Best-corrected visual acuity (BCVA) and macular thickness were measured by optical coherence tomography.
  • RESULTS: Under treatment, the size of the RHB did not change, but CME improved significantly.
  • However, CME recurred after the end of the treatment.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Hemangioblastoma / drug therapy. Indoles / therapeutic use. Macular Edema / drug therapy. Pyrroles / therapeutic use. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors. Retinal Neoplasms / drug therapy. von Hippel-Lindau Disease / drug therapy

  • Genetic Alliance. consumer health - Edema.
  • Genetic Alliance. consumer health - Hemangioblastoma.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12834696.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Indoles; 0 / Pyrroles; 71IA9S35AJ / Semaxinib; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


18. Taylor KL, Oates RK, Grane R, Leaman DW, Borden EC, Lindner DJ: IFN-alpha1,8 inhibits tumor-induced angiogenesis in murine angiosarcomas. J Interferon Cytokine Res; 2006 May;26(5):353-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interferon-alpha (IFN-alpha) has proved effective in the treatment of hemangiomas, hemangioblastomas, and Kaposi's sarcoma.
  • [MeSH-major] Hemangiosarcoma / blood supply. Hemangiosarcoma / drug therapy. Interferon-alpha / therapeutic use. Neovascularization, Pathologic / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Chemokine CXCL10. Chemokines, CXC / biosynthesis. Chemokines, CXC / blood. Disease Progression. Humans. Mice. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16689662.001).
  • [ISSN] 1079-9907
  • [Journal-full-title] Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • [ISO-abbreviation] J. Interferon Cytokine Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA089344-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chemokine CXCL10; 0 / Chemokines, CXC; 0 / Interferon-alpha
  •  go-up   go-down


19. Combes C, Redondo A, Rey A: [Contraception and neurology]. Ann Med Interne (Paris); 2002 Oct;153(6):363-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is however a formal contraindication for oral contraception, even with mini-dose contraceptives, for women with a history of cerebral venous thrombosis.
  • In case of migraine headache, which is also a risk factor of vascular disease (especially in case of aura), oral contraceptives should be discussed on an individual basis, depending on the presence of other risk factors.
  • Contraception has no effect on epilepsy but oral contraceptives may be inhibited by inducing anti-seizure drugs.
  • Non-inducing drugs are preferable.
  • The course of certain brain tumors known to express estrogen or progesterone receptors (particularly meningiomas and hemangioblastomas) may worsen with oral contraception, which is formally contradicted except when search for hormone receptors is negative.
  • Oral contraception has no influence in other disease such as multiple sclerosis
  • [MeSH-minor] Adult. Age Factors. Brain / pathology. Drug Synergism. Epilepsy / drug therapy. Female. Hemangioblastoma / chemistry. Humans. Meningioma / chemistry. Receptors, Estrogen / analysis. Risk Factors. Sclerosis. Vasodilation

  • MedlinePlus Health Information. consumer health - Migraine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12486383.001).
  • [ISSN] 0003-410X
  • [Journal-full-title] Annales de médecine interne
  • [ISO-abbreviation] Ann Med Interne (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Contraceptives, Oral, Hormonal; 0 / Receptors, Estrogen
  • [Number-of-references] 24
  •  go-up   go-down


20. Schuch G, de Wit M, Höltje J, Laack E, Schilling G, Hossfeld DK, Fiedler W, Scigalla P, Jacobs MS: Case 2. Hemangioblastomas: diagnosis of von Hippel-Lindau disease and antiangiogenic treatment with SU5416. J Clin Oncol; 2005 May 20;23(15):3624-6
MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case 2. Hemangioblastomas: diagnosis of von Hippel-Lindau disease and antiangiogenic treatment with SU5416.
  • [MeSH-major] Cerebellar Neoplasms / diagnosis. Hemangioblastoma / diagnosis. Indoles / therapeutic use. Neoplasm Recurrence, Local / diagnosis. Pyrroles / therapeutic use. von Hippel-Lindau Disease / diagnosis. von Hippel-Lindau Disease / drug therapy
  • [MeSH-minor] Angiogenesis Inhibitors / therapeutic use. Biopsy, Needle. Diagnosis, Differential. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging / methods. Male. Middle Aged. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908674.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Indoles; 0 / Pyrroles; 71IA9S35AJ / Semaxinib
  •  go-up   go-down


21. Jabary NS, Sarabia R, Sanchez T, Gordillo R: Midodrine treatment in the management of severe orthostatic hypotension after hemangioblastoma surgery. Acta Neurochir (Wien); 2007 Mar;149(3):303-5; discussion 305-6
Hazardous Substances Data Bank. Midodrine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Midodrine treatment in the management of severe orthostatic hypotension after hemangioblastoma surgery.
  • [MeSH-major] Cerebral Ventricle Neoplasms / surgery. Fourth Ventricle / surgery. Hemangioblastoma / surgery. Hypotension, Orthostatic / drug therapy. Midodrine / adverse effects. Postoperative Complications / drug therapy. Sympathomimetics / adverse effects
  • [MeSH-minor] Drug Administration Schedule. Female. Foramen Magnum / surgery. Humans. Hydrocephalus / surgery. Middle Aged. Ventriculoperitoneal Shunt

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17334671.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Sympathomimetics; 6YE7PBM15H / Midodrine
  •  go-up   go-down






Advertisement